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Background: Osteoarthritis (OA) is a common joint disease that causes disabilities in elderly adults. However, few
long-lasting pharmacotherapeutic agents with low side effects have been developed to treat OA. We evaluated the
therapeutic effects of intra-articular injections of hydrogels containing hyaluronic acid (HA) and doxycycline (DOX)
in a rabbit OA model.
Results: Thirteen week old New Zealand White rabbits undergone a partial meniscectomy and unilateral fibular
ligament transection were administered with either normal saline (NT), HA, DOX or HA-DOX hydrogels on day 0, 3,
6, 9 and 12; animals were also examined the pain assessment in every three days. The joint samples were taken at
day 14 post-surgery for further histopathological evaluation. The degree of pain was significantly attenuated after
day 7 post-treatment with both HA and HA-DOX hydrogels. In macroscopic appearance, HA-DOX hydrogel group
showed a smoother cartilage surface, no or minimal signs of ulceration, smaller osteophytes, and less fissure
formation in compare to HA or DOX treatment alone. In the areas with slight OA changes, HA-DOX hydrogel group
exhibited normal distribution of chondrocytes, indicating the existence of cartilage regeneration. In addition, HA-
DOX hydrogels also ameliorated the progression of OA by protecting the injury of articular cartilage layer and
restoring the elastoviscosity.
Conclusion: Overall, from both macroscopic and microscopic data of this study indicate the injectable HA-DOX
hydrogels presented as a long-lasting pharmacotherapeutic agent to apply for OA therapy.
Keywords: Osteoarthritis, Disease-modifying osteoarthritis drugs, Connective tissue structure-modifying agents,
Hyaluronic acid, DoxycyclineBackground
Osteoarthritis (OA) is a chronic and multifaceted degen-
erative joint disease in which the articular cartilage and
the surrounding extracellular matrix (ECM) are destroyed
[1,2]. It is associated with increasing age because the ar-
ticular cartilage of the joints may degrade with continual
wear. An imbalance between the repair and degradation
of the cartilage may disrupt the collagen matrix, resulting
in OA. Non-steroidal anti-inflammatory drugs, calci-
tonin, and glucosamine have been used to treat OA [3].* Correspondence: ccheng@tmu.edu.tw; chenchho@tmu.edu.tw
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reproduction in any medium, provided the orHowever, these agents either have serious side effects or
may not be ideal for long-term therapy. Recent studies
of OA therapeutics have focused primarily on the devel-
opment of disease-modifying osteoarthritis drugs
(DMOADs) and connective tissue structure-modifying
agents (CTSMAs) [4-7].
Doxycycline (DOX) has been used to treat the symp-
toms of OA [8-11]. The synthesis of inducible nitric
oxide synthase is inhibited by DOX, which suppresses
the secretion of matrix metalloproteinases (MMPs) by
chondrocytes, thus relieving the degradation of type II
collagen and aggrecan. In addition, DOX significantly
suppresses the production of inflammatory cytokines,
such as interleukin-1 (α/β) and interleukin-6, which in-
hibits inflammation in OA synovial cells and chondrocytes
[12-15]. In an anterior-cruciate-ligament rupture-induced
spontaneous OA model, DOX significantly improved theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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has also shown that DOX can slow the rate of joint-space
narrowing in the knees with established OA [14]. Thus,
the chondroprotective effects of the suppression of cata-
bolic cytokine cascades by DOX treatment may represent
the ideal properties of both DMOAD- and CTSMA-based
therapies for OA.
Hyaluronic acid (HA) occurs naturally in the ECM
and synovial fluid. Imbalances in HA stability can result
in the development of OA, and the joints of OA patients
have been shown to contain shorter HA fragments than
those found in normal joints [17,18]. The clinical out-
comes of intra-articular HA and derived products had
been critically reviewed, and proven to be an effective,
safe, and tolerable treatment for knee OA [19]. Intra-
articular injections of HA and other lubricating sub-
stances have been shown to relieve OA symptoms by
alleviating pain and irritation [20,21]. Inflammation re-
duces the viscoelasticity of synovial fluid, and intra-
articular injections of HA can compensate for the loss of
joint lubrication by adhering to the cartilage surfaces
and protecting them from damage [22-24]. It has been
reported that nonmodified HA only with a half-life of
10–13 h, while chemically modified HA product, such as
hylan G-F 20, was lasting to 8.8 ± 0.9 days [25,26]. The
rapid clearance and elimination of HA intra-articular in-
jection may limit its clinical usage; therefore, the im-
provements of longer residence time may extend the
therapeutic benefit and clinical applications.
We hypothesized that the combination of HA and
DOX in a hydrogel [27] might produce additive effects
in OA therapy through the anti-inflammatory and anal-
gesic effects of DOX and HA, respectively, and the in-
creased viscoelasticity of the synovial fluid resulting
from the high-molecular-weight hydrogel polymer. InTable 1 Rheological characteristics of hydrogels containing h
doxycycline (DOX) with Zn2+ and HA-DOX solutions without Z
G’ (Pa)
0.01 Hz 0.1 Hz 0.5 Hz 2
HA# 0.020 0.056 0.435 7
Hydrogel 25* 0.055 0.238 1.761 8
Hydrogel 50* 0.052 0.347 2.302 8
Hydrogel 100* 0.338 1.166 2.796 1
Solution 25* 0.001 0.053 1.941 3
Solution 50* 0.004 0.187 1.263 3
Solution 100* 0.003 0.012 1.202 2
Note: 0.5 Hz is the approximate frequency corresponding to the movement of the k
viscous modulus.
Hydrogel, containing 10 mg/mL HA and indicated concentrations of DOX with Zn2+
without Zn2+.
#Concentration of HA = 10 mg/mL.
*Different concentration of DOX (i.e. 25, 50,100) in μg/mL.
2.5 Hz is the approximate frequency corresponding to the movement of the knee jaddition, the slow release of DOX from the hydrogel
polymer may sustain its therapeutic effects. We pro-
duced an injectable HA-DOX hydrogel, and evaluated
its efficacy as an intra-articular treatment in a rabbit
model of OA.Results
Rheological characteristics of the HA-DOX hydrogels
The mixture of HA, DOX, and ZnCl in an aqueous solu-
tion produced a thermo-reversible, water-soluble hydro-
gel. Because it had been previously reported that the
higher-molecular-weight, more viscoelastic hylan G-F 20
has significantly greater pain-relieving properties than
does the lower-molecular-weight, less-viscoelastic HA
[24], the rheological characteristics (G’, dynamic elastic
modulus and G”, dynamic viscous modulus) of the HA-
DOX hydrogel and an HA-DOX mixture without zinc
cations were assessed over a range of DOX concentra-
tions (Table 1).
In the absence of zinc cations, increasing concentra-
tions of DOX caused progressive decreases in both the
G’ and the G” as the HA and DOX precipitated because
of charge interactions. Compared with the HA, both the
G’ and G” were higher for the HA-DOX hydrogel, with
the G’ and the G” increasing with DOX concentrations
in the presence of zinc cations, indicating that ionic
bonding between the HA and the DOX molecules had
occurred within the high-MW polymer. Moreover, as
the oscillating frequency decreased, both the G’ and the
G” decreased more slowly as the DOX concentration
was increased, which further indicated that a high degree
of DOX cross-linking had occurred. We concluded that
the viscoelasticity of the HA-DOX hydrogel was com-
parable to or greater than that of the HA.yaluronic acid (HA) and various concentrations of
n2+
G” (Pa)
.5 Hz 0.01 Hz 0.1 Hz 0.5 Hz 2.5 Hz
.056 0.071 0.763 4.160 13.170
.473 0.093 0.801 4.749 13.716
.574 0.261 0.839 4.910 13.970
0.363 1.087 2.055 6.492 16.895
.721 0.045 0.602 3.846 9.636
.969 0.049 0.489 3.160 10.004
.750 08.041 0.487 3.691 10.474
nee joint in walking; G’, dynamic elastic modulus; G”, dynamic
; Solution, containing 10 mg/mL HA and indicated concentrations of DOX
oint in running.
Figure 1 HA-DOX hydrogel showed low cytotoxicity. The
influence of DOX (A), HA (B), and the HA-DOX hydrogel (C) on the
survival of human chondrosarcoma cells SW1353 was assessed in 3
independent experiments using a tetrazolium-based cell viability
assay. The relative number of surviving cells were quantified and
normalized to that of the NT group, which represented 100%
survival (*p < 0.05, **p < 0.01).
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As shown in Figure 1A, SW1353 cell viability was not no-
ticeably influenced by 0.01 to 25 μg/mL DOX, whereas
50 μg/mL DOX significantly inhibited the survival of
SW1353 cells. Treatments of SW1353 cells with 0.01, 0.1,
1.0, and 4.0 mg/mL HA for 24 h showed no cytotoxicity
(Figure 1B). Treatments with HA-DOX hydrogels con-
taining 4 mg/mL HA and 0.0, 7.15, 14.3, or 28.6 μg/mL
DOX for 24 h did not reduce SW1353 cell viability or alter
cell morphology (Figure 1C).
Intra-articular HA-DOX hydrogel injections reduced pain
Following the surgical induction of OA, the percentage
weight distribution of the left-hind paw decreased sig-
nificantly in each group (Figure 2). The percentage
weight distribution values for both the NT and the DOX
groups decreased over the course of the experiment. In
the HA and HA-DOX hydrogel groups, the percentage
weight distributions showed gradual and significant in-
creases on 7, 10, and 13 d after surgery, compared with
the NT and DOX groups (Figure 2), indicating that the
intra-articular injection of the HA and the HA-DOX
hydrogel treatments exhibited analgesic effects.
Intra-articular HA-DOX hydrogel injections reduced OA
pathology
The macroscopic examination of the specimens showed
that the articular cartilage was rough and dull on both
the femoral and tibial surfaces. The most remarkable
damage in each group occurred at the femoral condyle,
the femoral trochlea, and the tibial plateau. The NT
group had the highest lesion scores for all parameters
among the various treatment groups, and the HA-DOX
hydrogel group had significantly lower scores for all pa-
rameters (Figure 3). Although the differences between
the HA and the HA-DOX hydrogel groups were not sta-
tistically significant for all OA features examined, lower
lesion scores for the loss of the superficial layer of the
femur, the presence of fibrillation, and the presence of
osteophytes of the femur and the tibia were recorded for
the HA-DOX hydrogel group. Overall, the intra-articular
injection of the HA-DOX hydrogel significantly inhibited
the progression of OA in the rabbit model.
The microscopic histological examination showed that
the intra-articular injection of the HA-DOX hydrogel re-
duced the loss of chondrocytes at the femoral condyles
Figure 2 Intra-articular HA-DOX hydrogel presented relieve the pain. Influence of intra-articular injection of NT, HA, DOX and HA-DOX
hydrogel groups on the left-hind paw percent-weight distribution. The results were compared to evaluate differences between the NT group
(p < 0.05, a) and the DOX group (p < 0.05, b).
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with either the HA-DOX hydrogel or the HA attenuated
lesion formation. The NT group had many chondrocytes,
whereas the DOX group had few. The clone parameter
(cluster formation) revealed a typical feedback situation.
The HA-DOX hydrogel group had the fewest chondrocyte
clones, whereas the DOX, HA, and NT groups showed
significant cloning of chondrocytes. The NT group
showed the lowest loss of proteoglycan. Both the HA and
the HA-DOX hydrogel groups showed reduced losses of
the superficial layer, compared with the DOX and NT
groups (Figure 6). Similar results were observed for
ulceration, fibrillation, osteophytes, fissures, and disorg-
anization of chondrocytes, with the HA and the HA-DOX
hydrogel groups displaying significantly lower scores for
most of the parameters. Overall, the HA-DOX hydrogel
treatment resulted in the greatest reductions in OA
pathology.
Discussion
In our study, the HA-DOX hydrogel was formed by
polymerizing electrostatic interactions between HA and
DOX molecules, followed by cross-linking through the
phenolic moieties of the immobilized DOX by zinc-
mediated chelation. Increasing DOX concentrations in
the hydrogel exhibited increased G’ and G” values for
the polymer, with the higher DOX concentrations
resulting in a more highly cross-linked structure that
displayed greater viscosity and viscoelasticity. Our re-
sults show that the enhanced rheological properties of
the HA-DOX hydrogel were beneficial for intra-articular
applications in OA therapy.When applied intra-articularly, HA covers the surface
of the cartilage, acting as a cushion that absorbs pressure
and vibration and prevents further erosion. The highly
viscous HA has been used in intra-articular injections to
reverse the loss of viscosity and viscoelasticity of the
synovial fluid resulting from inflammation and physical
wear [21]. Our data show that the HA-DOX hydrogel
possesses higher viscosity and viscoelasticity than those
of HA alone, suggesting that it may provide better
chondroprotective effects (Table 1). The cytotoxicity
evaluation showed that treatment with high concentra-
tions of DOX alone (50 μg/mL) was toxic to the
SW1353 chondrosarcoma cells. However, the HA-DOX
hydrogel displayed significantly lower cytotoxicity, com-
pared with similar concentrations of DOX (Figure 1).
These results suggest that the HA-DOX hydrogel may
maintain protective effects for longer periods than those
of either HA or DOX used alone.
Intra-articular application of HA promotes the nutri-
ent transport and waste excretion functions of synovial
fluid, and covers the articular surfaces to protect the car-
tilage. The adherence of HA to articular surfaces has
been reported to protect nerve endings that may be
exposed by thinner, degraded cartilage [28,29]. The pain-
relieving property of HA is an important disease-
modifying quality for clinical purposes. Thus, the increase
in viscosity and viscoelasticity of the HA-DOX hydrogel
indicates that it should produce similar effects. In a pro-
spective cohort study to evaluate pain and functional out-
comes from OA patients with intra-articular HA injection
over 6 months, HA was associated with lower functional
pain severity, which represented an increase in the quality
Figure 3 (See legend on next page.)
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Figure 3 Intra-articular HA-DOX hydrogel injections reduced the macroscopic appearance of OA pathology. Macroscopic appearance of
the articular surfaces of the femoral condyles (left panels) and the tibia plateau (right panels) of the NT (A), HA (B), DOX (C), and HA-DOX
hydrogel groups (D). In addition, the femur (E) and the tibia (F) samples were examined using surgical magnifying glasses to evaluate the
damage to the articular cartilage surfaces and the various parameters were scored as described in the Materials and methods. The results were
compared to evaluate differences between the NT group (p < 0.05, a) and the DOX group (p < 0.05, b).
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study had also reported the mid-term efficacy (2-year) of
intra-articular HA injection improve the joint structure
and relieve pain in patients with knee OA [31]. In our
in vivo experiments, the percentage weight distributions
of the injured hind paw were used as an indicator of the
analgesic effects of the treatments (Figure 2). The results
showed a significant analgesic effect following intra-
articular injection of the HA and the HA-DOX hydrogel,
compared with the DOX and NT treatments, on Days 7,
10, and 13 following the induction of OA and the initi-
ation of treatment. This indicates the HA-DOX hydrogel
can still retain the pain-relieving property of HA; however,
its long-term effect of pain-reliving need be further
studied.
The macroscopic examination revealed that both the
HA and the HA-DOX hydrogel treatments diminished
OA features, compared with the NT and DOX treatments.
Moreover, the HA-DOX hydrogel group exhibited greater
therapeutic effects than those observed in the HA group.
However, intra-articular injection of DOX alone did not
abrogate the OA pathology, compared with the results ob-
served in the NT group (Figures 3, 4, and 5). Histopatho-
logical findings (Figures 4 and 5) mirrored the results of
the macroscopic evaluation and pain assessment. Both the
HA and the HA-DOX hydrogel treatments reduced cartil-
age degradation at the femoral condyles and the tibial plat-
eau, and effectively reduced the loss of the superficial layer,
ulceration, the production of osteophytes, the creation of
fissures, and the disorganization of cartilage, compared
with the NT and DOX treatments (Figures 4 and 5). As the
results of macroscopic examination, the chondroprotective
effects of HA-DOX hydrogel treatment were superior to
those of the HA treatment. The therapeutic treatments
had started immediately following surgery in this study that
may limit the therapeutic outcomes interpreting. Intra-
articular hylan G-F 20 injection in 4 weeks post-operatively
to the same model had also been reported the protective
effects in maintains cartilage integrity and decreases osteo-
phyte formation [32]. This may imply the potential of the
HA-DOX hydrogel in application to OA models with the
onset of symptoms. Future studies with different thera-
peutic regimens of HA-DOX hydrogel could provide add-
itional support to our current findings.
The loss of chondrocytes and of proteoglycan scores
for the NT group was lower than that of the HA group
and that of the HA and HA-DOX hydrogel groups,respectively. This may result in a feedback phenomenon,
in which a greater amount of chondrocytes produced
comparatively greater amounts of proteoglycan. However,
since the NT group presented similar proteoglycan level
to normal groups, it still cannot rule out the possibility
of the adversary effects of proteoglycan depletion fol-
lowing the treatments. As erosion and loss of cartilage
occurred, the remaining chondrocytes secreted more
glycoprotein for bone regeneration, resulting in the pro-
duction of osteophytes. The NT group had the highest
score of osteophytes; this may further support the
involvement of such feedback. The clone parameter
assessed the aggregation of chondrocytes, which may
also result from the feedback phenomenon. Aggregation
results from abnormal cell proliferation following cartil-
age destruction or chondrocyte perturbations. Thus,
clones can serve as signs of altered cartilage. However,
the reliability of this inference has not been thoroughly
established.
In addition to HA-DOX hydrogel, several different HA-
derived combination compounds were recently reported
the therapeutic effects by intra-articular injection in rabbit
OA model. Celecoxib-loaded liposomes embedded in HA
gel combination was more effective than a single drug in
pain control and cartilage protection [33]. Intra-articular in-
jection of collagen tripeptide, and collagen tripeptide and
HA mixtures seemed to be effective for the initiation period
of cartilage degeneration partly by promotion of type II col-
lagen synthesis and prevention of proteoglycan loss [34].
These findings suggest the developing potential of HA-
derived combination compounds in the OA therapy.
It is unlikely that the beneficial effects of the HA-DOX
hydrogel treatment can be attributed to a temporary en-
hancement of the viscoelasticity and viscosity of the syn-
ovial fluid. Based on the demonstrated anti-inflammatory
effects of DOX in clinical applications, the HA-DOX
hydrogel therapy possibly produced disease-modifying
biological actions that influenced the progression of OA
in the rabbit model. Thus, the HA-DOX hydrogel repre-
sents an ideal DMOAD and CTSMA. The long-term
therapeutic effects of intra-articular HA-DOX hydrogel
treatment in chronic OA warrants further investigation.
Conclusions
The HA-DOX hydrogel, composed of a polymer of HA
and DOX with zinc cations, possessed higher viscosity and
viscoelasticity, and provided better chondroprotective
Figure 4 Intra-articular HA-DOX hydrogel injections reduced the attenuated microscopic appearance of femoral condyles in OA.
Histological examinations of hematoxylin and eosin stained sections of the cartilage in the femoral condyles at 150X (left panels) and 300X (right
panels) magnifications. The samples from the groups were treated with NT (A), HA (B), DOX (C), and HA-DOX hydrogel groups (D) separately. The
normal-young group (13-week-old rabbits) (E) and the normal-old group (40-week-old rabbits) (F) did not receive intra-articular treatments. The
various features of OA pathology were scored on a scale of 0 to 4, with 4 representing OA lesions of the worst possible severity (G), as described
in the Materials and methods. The results were compared to evaluate differences between the NT group (p < 0.05, a); the DOX group (p < 0.05,
b); and the HA group (p < 0.05, c).
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Figure 5 Intra-articular HA-DOX hydrogel injections reduced the attenuated microscopic appearance of tibial plateau in OA.
Histological examinations of hematoxylin and eosin stained sections of the cartilage in the tibial plateau at 150X (left panels) and 300X (right
panels) magnifications. The samples from the NT (A), HA (B), DOX (C), and HA-DOX hydrogel groups (D) were processed separately. The normal-
young group (13-week-old rabbits) (E) and the normal-old group (40-week-old rabbits) (F) did not receive intra-articular treatments. The various
features of OA pathology were scored on a scale of 0 to 4, with 4 representing OA lesions of the worst possible severity (G), as described in the
Materials and methods. The results were compared to evaluate differences between the NT group (p < 0.05, a); the DOX group (p < 0.05, b); and
the HA group (p < 0.05, c).
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Figure 6 The expression pattern of proteoglycan in the microscopic appearance of OA pathology. Histological examination of Alcian-blue
stained sections of cartilage from the femoral condyles (left panels) and the tibial plateau (right panels) at 300 X magnifications. The samples
from the NT (A), HA (B), DOX (C), and HA-DOX hydrogel groups (D) were processed separately. The normal-young group (13-week-old rabbits)
(E) and the normal-old group (40-week-old rabbits) (F) did not receive intra-articular treatments.
Lu et al. BMC Veterinary Research 2013, 9:68 Page 9 of 12
http://www.biomedcentral.com/1746-6148/9/68effects than those of an HA alone. Therefore, the injectable




The human chondrosarcoma cell line, SW1353, was
obtained from American Type Culture Collection
(Manassas, VA, USA). We used 10 mg/mL ARTZ-Dispo
HA (Seikagaku, Tokyo, Japan) in all of our experiments.
The ARTZ-Dispo HA has a weight-average molecular
weight (MW) of 60 to 120 kDa and a viscosity-average
MW of 1650 kDa. DOX and zinc chloride (ZnCl2) were
purchased from Sigma (St Louis, MO, USA), and the
normal saline was provided by the Sin-Tong Company
(Taoyuan, Taiwan).
Hydrogel preparation and characterization
The HA-DOX hydrogels were prepared as previously de-
scribed [27], except that we replaced the magnesium
ions with zinc ions (2:1 DOX to Zn2 + ratio). The pH of
the HA, ZnCl2, and DOX aqueous solutions were adjusted
to 7.0 with a 50 mM phosphate buffer. The solutions weredispensed and cooled overnight in a refrigerator to fa-
cilitate polymerization. The resulting hydrogels were
stored in a refrigerator and used within 1 d. The visco-
elastic properties of the hydrogels were measured using
a Haake RheoStress 1 rotation rheometer (Thermo
Fisher, Waltham, MA, USA). The dynamic shear mod-
uli, G’ (elasticity) and G” (viscosity), were determined
using the oscillation mode with a frequency range of
0.01 to 2.5 Hz.
Cell viability
Following the DOX, HA, and HA-DOX hydrogel treat-
ments, the SW1353 cell viability was determined using a
tetrazolium-based colorimetric (MTT) assay. Detergent
was used to dissolve the formazan crystals in wells be-
fore directly measuring the absorbance at 570 nm with a
spectrophotometer.
Experimental OA model
All our animal protocols were approved by the Experi-
mental Animal Review Committee of Taipei Medical
University. Thirteen-week-old male New Zealand white
rabbits were used for our experimental OA model
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score [35]. The in vivo animal experiments were performed
using aseptic techniques. The rabbits were anesthetized
using Zoletil (Zoletil-Virbac, Carros, France) and Rompun
(Bayer, Leverkusen, Germany). The left knee joint was in-
cised approximately 2 cm down the lateral aspect of the
patella to expose and cut the lateral-collateral ligament
(fibular ligament). The end of the popliteus tendon was in-
cised to expose the lateral meniscus, and the lateral menis-
cus was resected in the midsection for 3.0 to 4.0 mm to
detach approximately one-third of the meniscus. The sub-
dermal muscular layer and skin were closed using knotted
absorbable sutures and nylon sutures. A 0.22 mL injection
of enrofloxacin (China Chemical and Pharmaceutical,
Hsinchu, Taiwan) was administered subdermally near the
thigh to avoid suppuration. A partial meniscectomy was
performed immediately before the administration of the
test drugs. The animals were housed individually in 350 ×
527 × 350 mm (W×D×H) steel cages at 22 ± 3°C and
55% ± 20% humidity. Animals were fed RC4 pellet-type
laboratory-animal food with no additional calcium supple-
ment through a stainless steel pellet feeder, and tap water
was provided continually.
Experimental design
Following the partial meniscectomy of the left knee
joint, the rabbits were divided into the NT (n = 8), HA
(n = 8), DOX (n = 7), and HA-DOX GEL (n = 8) study
groups, and received 0.2 mL intra-articular injections of
normal saline, DOX (87.5 μg/mL), HA (10 mg/mL), or
the HA-DOX hydrogel (10 mg/mL HA and 87.5 μg/mL
DOX), respectively, to the meniscetomized left cavity of
the knee joint using a 1 mL syringe with a 26G hypoder-
mic needle immediately following surgery. The injec-
tions were repeated on 3, 6, 9, and 12 d following the
meniscectomy.
Pain assessment
Triplicate measurements of the hind-paw weight distri-
butions were recorded using 2 scales that independently
measured the weight borne by each hind paw. The
mean percentage (%) weight distribution of the left-
hind paw was calculated 1 d before surgery and on 1, 4,
7, and 13 d after surgery according to the following
equation [36]:
% weight distribution of left hind paw
¼ left weight




After the rabbits were euthanized, treated knee joint
specimens were collected by osteotomy 3 cm above andbelow the knee joint. The specimens were fixed in 10%
buffered formalin for 24 h. Fixed specimens were cleared
of soft tissues and ligaments to allow the gross examin-
ation of the articular surfaces of the femoral condyles
and the tibial plateau for the scoring of the features of
OA pathology.
Macroscopic and microscopic specimen examinations
The macroscopic examination of the specimens was
performed using a surgical magnifying glass to evaluate
the OA progression based on a modification of the pa-
rameters described by Colombo et al. (1983b). The loss
of the superficial layer, the cartilage erosion, the loss of
the cartilage luster, the presence of osteophytes, and the
presence of fissures were evaluated based on the loca-
tion, type, and size of the pathological feature. Digital
photographs of the articular surfaces were recorded.
Histological sections were taken at both femoral con-
dyles, the femoral trochlea, the internal tibial plateau,
and the lateral tibial plateau. The specimens were separ-
ately stained with hematoxylin and eosin (H&E), peri-
odic acid Schiff stain, and Alcian blue stain. In the
microscopic examination, 9 histological parameters were
scored based on a previously described grading system
[37] as follows: loss of the superficial layer, the presence
of ulceration or erosion (surface fragmentation), the pres-
ence of fibrillation, the presence of fissures (V-shaped
clefts), the presence of osteophytes and/or chondrophytes,
the loss of stainable proteoglycan, the disorganization of
chondrocytes, the presence of clones, and the loss of
chondrocytes.
Every histological parameter was scored on a scale of 0
to 4 according to the severity of the OA, by which cartil-
age with an appearance that was identical to healthy car-
tilage at the same age was graded as 0, and OA lesions
of the worst possible severity were scored as 4. Cartilage
thickness was microscopically measured at 10X magnifi-
cation in increments of 0.01 mm of actual thickness,
where 1 cm of the microscopic scale corresponded to
0.39 mm of actual thickness. The total score of all 5 pa-
rameters represented the severity of OA progression in
each histological section. The sum of all scores from all
histological sections of each animal represented the total
score for that animal. The statistical analysis was based
on the median and the mean of the sums of the total
scores of all the animals in each treatment group.
Statistical analysis
The data are expressed as the mean ± the standard devi-
ation of the various measurements. The statistical sig-
nificance of intergroup differences was analyzed using
one-way analysis of variance (ANOVA) and the Duncan
post-hoc test. Differences with a P value less than 0.05
were considered statistically significant.
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